AAAAAA
Results:
1-18
|
Results: 18
Authors:
MONTGOMERY DD
GOLD SN
GONTKOVSKY ST
MIGOYA JM
ZIMMERMAN SW
Citation: Dd. Montgomery et al., FROM VIDEO FANTASY TO PHYSIOLOGICAL AND PSYCHOLOGICAL REALITY, Applied psychophysiology and biofeedback, 23(2), 1998, pp. 123-123
Authors:
WAKEEN M
ZIMMERMAN SW
Citation: M. Wakeen et Sw. Zimmerman, ASSOCIATION BETWEEN HUMAN RECOMBINANT EPO AND PERIPHERAL VASCULAR-DISEASE IN DIABETIC-PATIENTS RECEIVING PERITONEAL-DIALYSIS, American journal of kidney diseases, 32(3), 1998, pp. 488-493
Authors:
DANCEY EA
WAKEEN MJ
ZIMMERMAN SW
Citation: Ea. Dancey et al., CARDIAC AND PERIPHERAL VASCULAR MORBIDITY IN DIABETICS (DM) - COMPARISON OF HEMODIALYSIS (HD) AND PERITONEAL-DIALYSIS (PD), Journal of the American Society of Nephrology, 8, 1997, pp. 1003-1003
Authors:
JOHNSON CA
TAYLOR CA
ZIMMERMAN SW
CHEVALIER P
PASQUIER O
BAYBUTT RI
Citation: Ca. Johnson et al., PHARMACOKINETICS OF QUINUPRISTIN DALFOPRISTIN (SYNDERCID(R) RP-59500)IN PATIENTS RECEIVING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD)/, Journal of the American Society of Nephrology, 8, 1997, pp. 1217-1217
Authors:
ABDELRAHMAN EM
WAKEEN M
ZIMMERMAN SW
Citation: Em. Abdelrahman et al., CHARACTERISTICS OF LONG-TERM PERITONEAL-DIALYSIS SURVIVORS - 18 YEARSEXPERIENCE IN ONE-CENTER, Peritoneal dialysis international, 17(2), 1997, pp. 151-156
Authors:
WAKEEN MJ
ZIMMERMAN SW
Citation: Mj. Wakeen et Sw. Zimmerman, PERIPHERAL VASCULAR-DISEASE IN DIABETIC-PATIENTS ON PD RECEIVING RHU-ERYTHROPOIETIN (EPO), Journal of the American Society of Nephrology, 7(9), 1996, pp. 1097-1097
Authors:
ZIMMERMAN SW
OXTON LL
BIDWELL D
WAKEEN M
Citation: Sw. Zimmerman et al., LONG-TERM OUTCOME OF DIABETIC-PATIENTS RECEIVING PERITONEAL-DIALYSIS, Peritoneal dialysis international, 16(1), 1996, pp. 63-68
Authors:
TAYLOR CA
ABDELRAHMAN E
ZIMMERMAN SW
JOHNSON CA
Citation: Ca. Taylor et al., CLINICAL PHARMACOKINETICS DURING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS, Clinical pharmacokinetics, 31(4), 1996, pp. 293-308
Authors:
ABDELRAHMAN EM
WAKEEN MJ
ZIMMERMAN SW
Citation: Em. Abdelrahman et al., CHARACTERISTICS OF LONG-TERM PERITONEAL-DIALYSIS (PD) SURVIVORS, Journal of the American Society of Nephrology, 6(3), 1995, pp. 516-516
Authors:
ATESHKADI A
JOHNSON CA
FOUNDS HW
ZIMMERMAN SW
Citation: A. Ateshkadi et al., SERUM ADVANCED GLYCOSYLATION END-PRODUCTS IN PATIENTS ON HEMODIALYSISAND CAPD, Peritoneal dialysis international, 15(3), 1995, pp. 129-133
Authors:
WAKEEN M
OXTON L
ZIMMERMAN SW
Citation: M. Wakeen et al., FAVORABLE LONG-TERM OUTCOME OF TYPE-I DIABETES (DM) PATIENTS (PTS) RECEIVING PERITONEAL-DIALYSIS, Journal of the American Society of Nephrology, 5(3), 1994, pp. 483-483
Authors:
WAKEEN MJ
ZIMMERMAN SW
BIDWELL D
Citation: Mj. Wakeen et al., VISCUS PERFORATION IN PERITONEAL-DIALYSIS PATIENTS - DIAGNOSIS AND OUTCOME, Peritoneal dialysis international, 14(4), 1994, pp. 371-377
Authors:
OXTON LL
ZIMMERMAN SW
ROECKER EB
WAKEEN M
Citation: Ll. Oxton et al., RISK-FACTORS FOR PERITONEAL DIALYSIS-RELATED INFECTIONS, Peritoneal dialysis international, 14(2), 1994, pp. 137-144
Authors:
LEE FT
LEAHYGROSS KM
HAMMOND TG
WAKEEN MJ
ZIMMERMAN SW
Citation: Ft. Lee et al., PNEUMOPERITONEUM IN PERITONEAL-DIALYSIS PATIENTS - SIGNIFICANCE OF DIAGNOSIS BY CT, Journal of computer assisted tomography, 18(3), 1994, pp. 439-442
Authors:
HALSTENSON CE
WONG MO
JOHNSON CA
ZIMMERMAN SW
ONORATO JJ
KEANE WF
DOEPNER M
SIA L
TANTILLO K
BANSAL S
KUYE O
YACOBI A
FAULKNER R
LATHIA CD
Citation: Ce. Halstenson et al., PHARMACOKINETICS OF TAZOBACTAM M1 METABOLITE AFTER ADMINISTRATION OF PIPERACILLIN TAZOBACTAM IN SUBJECTS WITH RENAL IMPAIRMENT/, Journal of clinical pharmacology, 34(12), 1994, pp. 1208-1217
Authors:
BOHENEK WS
JOHNSON CA
ATESHKADI A
OXTON LL
ZIMMERMAN SW
Citation: Ws. Bohenek et al., EFFECT OF PERITONITIS ON PLASMA AND DIALYSATE ALPHA(1)-ACID GLYCOPROTEIN CONCENTRATIONS IN PERITONEAL-DIALYSIS PATIENTS, Clinical pharmacy, 12(8), 1993, pp. 602-605
Authors:
ATESHKADI A
JOHNSON CA
OXTON LL
HAMMOND TG
BOHENEK WS
ZIMMERMAN SW
Citation: A. Ateshkadi et al., PHARMACOKINETICS OF INTRAPERITONEAL, INTRAVENOUS, AND SUBCUTANEOUS RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS, American journal of kidney diseases, 21(6), 1993, pp. 635-642
Authors:
JOHNSON CA
ATESHKADI A
ZIMMERMAN SW
HUGHES GS
CRAIG WA
CAREY PM
BORIN MT
Citation: Ca. Johnson et al., PHARMACOKINETICS AND EX-VIVO SUSCEPTIBILITY OF CEFPODOXIME PROXETIL IN PATIENTS RECEIVING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS, Antimicrobial agents and chemotherapy, 37(12), 1993, pp. 2650-2655
Risultati:
1-18
|